5P Exploratory biomarker analysis from neoadjuvant atezolizumab, pertuzumab, trastuzumab plus docetaxel (NEO-PATH) in HER2+ early breast cancer

H. K. Ahn,K. Park, S. H. Sim, K. J. Suh, M. H. Kim,W-Y. Park,Y-L. Choi,S-A. Im,K. H. Jung,Y. H. Park

Annals of Oncology（2022）

Cited 0|Views9

No score

Abstract

Neoadjuvant atezolizumab plus docetaxel, trastuzumab and pertuzumab therapy showed favorable efficacy and safety profiles in HER2-positive early breast cancer (EBC) in NEO-PATH phase 2 study, which provided evidence of combining immunotherapy and anti-HER2 treatment as a potential new therapeutic option. We evaluated potential genomic biomarkers in NEO-PATH trial.

Translated text

Key words

neoadjuvant atezolizumab,early breast cancer,breast cancer,exploratory biomarker analysis,her2+,neo-path

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined